Physiological pharmacokinetic models are developed for the distribution and disposition of drugs and environmental contaminants. These models provide a plausible set of equations that can be used to extrapolate data from experimental systems to humans and provide a rational basis for improvement of chemotherapy, chemoprevention, and risk assessment. Regional drug delivery has been emphasized with specific work on delivery of drugs to the central nervous system, peritoneal cavity and lung. (1) Direct infusion of proteins and other agents to the brain has considerable potential for treatment of a variety of tumors and neurodegenerative disorders. A major problem has been the inability to track the spatial and temporal distribution of the infused material. Work in progress has examined the applicability of imaging methods to follow the distribution of infused proteins. Computerized tomography and magnetic resonance imaging have been compared with the distribution of proteins determined by quantitative autoradiography in the monkey brain. (2) Peritoneal drug administration can provide a large pharmacokinetic advantage. We continue our interest in the mechanisms of absorption of drugs from the peritoneal cavity and their quantitative characterization. The pharmacokinetics of gemcitabine following intraperitoneal administration have been examined in connection with a combined clinical trail with surgery and radiation. (3) Lung cancer originates in the epithelial cells lining the airways. It appears that there is a lengthy process leading to the development of clinically observable disease. Early detection by molecular diagnostics may provide an opportunity to intervene in the progression of the disease if appropriate agents are available and can be delivered to the epithelial cells. The regional nature of the disease suggests the possibility of chemoprevention by the administration of appropriate aerosols to the lung. Pharmacokinetic issues include the spatial and temporal distribution of agents within the lung, clearance mechanisms from the lung, and the pharmacokinetic advantage achievable by this approach. Similar chemoprevention strategies may be useful for a variety of other malignancies.
